Physician profile
Anthony C Smith
NPI 1184605420
$4,316.15
in general payments reported to CMS, 2019-2025
28 companies · $196 in 2025
The $196 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $679 · 2021: $849 · 2022: $638 · 2023: $433 · 2024: $281 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $641.33 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.93 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $370.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $319.69 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $305.80 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $285.81 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $264.38 | 2019-2022 | |
| Abbvie INC. | $195.54 | 2021-2023 | Teflaro |
| Pfizer INC. | $184.85 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $177.09 | 2019-2023 | Ultomiris |
| Allergan, INC. | $142.53 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $124.98 | 2019 | |
| Amgen INC. | $119.69 | 2020-2024 | Repatha |
| Otsuka America Pharmaceutical, INC. | $119.06 | 2019 | |
| Vifor Pharma, INC. | $92.88 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $69.63 | 2019-2020 | |
| Melinta Therapeutics, LLC | $68.39 | 2021-2024 | Orbactiv, Kimyrsa, Vabomere |
| Gilead Sciences, INC. | $64.71 | 2021-2025 | Veklury |
| Alkermes, INC. | $40.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2021-2025 | Jardiance |
| Janssen Scientific Affairs, LLC | $30.36 | 2023 | Xarelto |
| Abbott Laboratories | $29.19 | 2025 | Freestyle Libre 3 |
| Recor Medical INC | $25.78 | 2024 | Paradise Renal Denervation System |
| Inari Medical, INC. | $25.53 | 2022 | |
| Urgo Medical North America, LLC | $19.70 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Smith+Nephew, INC. | $18.27 | 2022 | |
| Incyte Corporation | $15.44 | 2023 | Jakafi |
| Chiesi USA, INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.